Robert Mayer M.D.

Stephen B. Kay Family Professor of Medicine, Department of Medicine, Harvard Medical School

Attending Physician, MGH Cancer Center, Massachusetts General Hospital

Consulting Staff, Department of Medicine, Beth Israel Deaconess Medical Center

Senior Physician, Department of Medicine, Brigham and Women's Hospital

Vice Chair for Academic Affairs, Department of Medical Oncology, Dana-Farber Cancer Institute

Contact Info

Robert Mayer
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: D-1608
Phone: 6176323474
Fax: 6176322260
No email address available.

Assistant

Kim Bremner
Phone: 6176323474
Fax: 6176322260
kim_bremner@dfci.harvard.edu

DF/HCC Program Affiliation

Co-Leader, Gastrointestinal Malignancies Program

DF/HCC Associations

Member, Center Scientific Council

Research Abstract

Gastrointestinal cancer ranks second only to respiratory cancer in the number of new cases and annual deaths in the United States each year. The term gastrointestinal cancer refers to malignant conditions of the esophagus, stomach, liver, biliary system, pancreas, small bowel, large bowel (i.e., colon and rectum), and anus.

Our efforts include the identification and counseling of families at high risk of developing such disorders, the study of medical interventions to prevent the diseases, screening techniques to detect them at a preclinical stage, and the development of innovative treatment plans for diagnosed patients. Such efforts involve the participation of medical, radiation, and surgical oncologists, pathologists, gastroenterologists, social workers, and genetic counselors.

The Gastrointestinal Cancer Committee of the Cancer and Leukemia Group B, chaired by Dr. Mayer, is a multi-institutional collaboration supported by the National Cancer Institute. This research organization designs clinical trials conducted at DFCI and elsewhere throughout the United States.

Our work has been instrumental in studies which have defined optimal post-surgical (i.e. adjuvant) treatment for colon and rectal cancer and newer approaches to localized and advanced pancreatic cancer. In addition, Dr. Mayer has brought such new compounds as cetuximab to Dana-Farber for clinical testing.

Publications

Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999 Mar 18; 340(11):858-68
PMID: 10080850
Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994 Oct 6; 331(14):896-903
PMID: 8078551

Advanced search
DF/HCC Directory Login Change Account Settings Benefits Requirements Responsibilities Applying for Membership Update Member Profile	Robert Mayer M.D. Stephen B. Kay Family Professor of Medicine, Department of Medicine, Harvard Medical School Attending Physician, MGH Cancer Center, Massachusetts General Hospital Consulting Staff, Department of Medicine, Beth Israel Deaconess Medical Center Senior Physician, Department of Medicine, Brigham and Women's Hospital Vice Chair for Academic Affairs, Department of Medical Oncology, Dana-Farber Cancer Institute Contact Info Robert Mayer Dana-Farber Cancer Institute 44 Binney Street Boston, MA, 02115 Mailstop: D-1608 Phone: 6176323474 Fax: 6176322260 No email address available. Assistant Kim Bremner Phone: 6176323474 Fax: 6176322260 kim_bremner@dfci.harvard.edu DF/HCC Program Affiliation Co-Leader, Gastrointestinal Malignancies Program DF/HCC Associations Member, Center Scientific Council Research Abstract Gastrointestinal cancer ranks second only to respiratory cancer in the number of new cases and annual deaths in the United States each year. The term gastrointestinal cancer refers to malignant conditions of the esophagus, stomach, liver, biliary system, pancreas, small bowel, large bowel (i.e., colon and rectum), and anus. Our efforts include the identification and counseling of families at high risk of developing such disorders, the study of medical interventions to prevent the diseases, screening techniques to detect them at a preclinical stage, and the development of innovative treatment plans for diagnosed patients. Such efforts involve the participation of medical, radiation, and surgical oncologists, pathologists, gastroenterologists, social workers, and genetic counselors. The Gastrointestinal Cancer Committee of the Cancer and Leukemia Group B, chaired by Dr. Mayer, is a multi-institutional collaboration supported by the National Cancer Institute. This research organization designs clinical trials conducted at DFCI and elsewhere throughout the United States. Our work has been instrumental in studies which have defined optimal post-surgical (i.e. adjuvant) treatment for colon and rectal cancer and newer approaches to localized and advanced pancreatic cancer. In addition, Dr. Mayer has brought such new compounds as cetuximab to Dana-Farber for clinical testing. Publications Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999 Mar 18; 340(11):858-68 PMID: 10080850 Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994 Oct 6; 331(14):896-903 PMID: 8078551
Site Map Site Feedback Web Privacy Policy